XOMA 052

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
41Giant cell arteritis10
46Malignant rheumatoid arthritis1
50Dermatomyositis9
IDDisease name (Link within this page)Number of trials
56Behcet disease7
106Cryopyrin-associated periodic syndrome1

41. Giant cell arteritis


Clinical trials : 160 / Drugs : 183 - (DrugBank : 35) / Drug target genes : 32 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

50. Dermatomyositis


Clinical trials : 264 / Drugs : 298 - (DrugBank : 66) / Drug target genes : 71 - Drug target pathways : 173 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

56. Behcet disease


Clinical trials : 110 / Drugs : 137 - (DrugBank : 40) / Drug target genes : 40 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

106. Cryopyrin-associated periodic syndrome


Clinical trials : 57 / Drugs : 38 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 47 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries